Maribavir for Prevention of CMV After Stem Cell Transplants
Status:
Completed
Trial end date:
2006-04-05
Target enrollment:
Participant gender:
Summary
Cytomegalovirus (CMV) infections remain a significant problem following various types of
transplants that are associated with strong immunosuppressive therapy. Maribavir is a new
oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV
drugs. This study will test the safety and anti-CMV activity of different doses of maribavir
when given as CMV prophylaxis following stem cell transplants.